The FDA's Ophthalmic Devices Panel issues a mixed vote on the efficacy of AcuFocus's Kamra intraocular implant in improving near-vision in patients with presbyopia. A panel of FDA experts today was divided on whether the federal watchdog agency should approve the AcuFocus Kamra Inlay, a 1st-of-a-kind permanent corneal implant for the improvement of near and intermediate vision in patients with presbyopia, a form of age-related far-sightedness. Of the 8 panelists 7 voted that Kamra is effective, the panel was evenly split on the question of safety, with the chairman breaking the tie and voting against.
Help employers find you! Check out all the jobs and post your resume.
